U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07444801) titled 'Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact' on Oct. 02, 2025.
Brief Summary: Hypothesis: Treatment with tralokinumab in patients with moderate-to-severe AD involving the genital region is expected to lead to significant improvements in PROs and clinical disease severity. These improvements will be assessed using genital-specific scoring systems, validated PRO instruments, and non-invasive imaging techniques, including optical coherence tomography (OCT), confocal microscopy, or line-field optical coherence tomography (LC-OCT). Objectives: To investigate improvements in gen...